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Purpose/Objective 
Background:  
Bladder preservation combining surgery and radiotherapy 
could maintain quality of life without compromising tumor 
control in selected patients with bladder carcinoma. Several 
reports confirm good results. Prognosis of patients presented 
with recurrence after primary treatment with this regimen is 
not well known. 
We report the long term results of treated recurrences after 
bladder preservation treatment with brachytherapy. 
Materials and Methods: Between 1989 and 2011, 192 
selected patients with muscle-invasive bladder cancer were 
treated with a combined regimen of preoperative external 
radiotherapy, and subsequent surgical exploration with or 
without partial cystectomy and interstitial brachytherapy. 
Data of patients presenting with local recurrence after this 
regimen were retrospectively collected. The primary end 
points were local recurrence-free survival (LRFS) and overall 
survival (OS) (after the treatment of recurrence). 
Complications of the secondary treatment were reported. 
Results: The median follow-up after primary treatment was 
105 months (6-212 months). In 40/192 (20.8%) patients a 
local recurrence was detected. Four patients were excluded 
because of lack of data.  
Treatment of the local recurrence was performed in 28/36 
(78%) patients. For 18 patients a salvage cystectomy was 
performed; 10 patients were treated with transurethral 
resection followed by intravesical BCG. In 4 patients 
cystectomy procedures were discontinued. 
The local recurrence was muscle invasive in 19 patients; 
mostly treated by salvage cystectomy (14/19). The LRFS after 
the treatment of recurrence was 70% and 55% after 2 and 5 
years, respectively. The OS 2 and 5 years after treatment was 
71% and 34%, respectively. The LRFS of the 18 patients 
treated with salvage cystectomy 71% after 2 years as well 5 
years and the OS was 67% and 36% after 2 and 5 years, 
respectively. 
In 11/18 (61%) patients treated with cystectomy, surgical 
complications were reported, 6/11 patients with Clavien 
Dindo complications grade ≥ 3.  
Conclusions: The LRFS of patients treated for local 
recurrence after bladder-sparing regimen using 
brachytherapy offers good long-term oncological outcome. 
Salvage cystectomy gave the best long term local control, 
unfortunately with more surgical complications.  
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Purpose/Objective: Interstitial multicatheter brachytherapy 
is the most frequently used technique of partial breast 
irradiation, and could be used to deliver surgical bed boost 
and moreover exclusively accelerated partial breast 
irradiation (APBI). Our purpose is to evaluate our clinical 
results using both options of high dose rate (HDR) 
brachytherapy, in a risk adapted way.  
Materials and Methods: Between 1999 and 2014, 276 breast 
cancer patients has been treated with brachytherapy in our 
institution, with a mean follow-up of 65 months. It has been 
used as a boost combined with external beam radiotherapy 
(EBRT) in 125 patients with a median dose of 8 Gy in 
tumorectomy bed added to conventional doses of EBRT (50 
Gy). In the others 151 patients it has been delivered as 
exclusive APBI, with a dose of 32 Gy separated in 8 fractions 
of 4 Gy. ASTRO and GEC-ESTRO APBI recommendations has 
been registered for every patient.  
Results: The mean age at diagnosis was 61.67 years (range: 
24-92), 80.4% presented a postmenopausal status, in 82% 
tumor size was < 2 cm, 47 % grade I, 35% grade II and 13% 
grade III. Using APBI GEC-ESTRO recommendations, patients 
were classified as low risk in 41%, intermediate risk 21% and 
high risk 38%. For the ASTRO criteria, patients were classified 
as suitable 31%, cautionary 37% and unsuitable 32%. Most 
intermediate and high risk patients treated with APBI were 
elder than 70 years or they lived far from our institution. 
With a mean follow-up of 65 months (range: 4-179), actuarial 
local disease free survival was 98.1% at 5 years and 94.1% at 
10 years. Actuarial cause specific survival was 96.8% at 5 
years and 94.2% at 10 years. Five years and 10 years actuarial 
overall survival were 90.1% and 85.7% respectively.  
For the whole group, the best risk fit was obtained using 
GEC-ESTRO recommendations for APBI, with a local disease 
free survival at 5 and 10 years of 100% for those patients with 
low risk of recurrence. 
Conclusions: HDR risk adapted brachytherapy represents a 
good approach in breast cancer conservative treatment in 
terms of local control and survival. GEC-ESTRO 
recommendations has demonstrated to be a good tool to 
select patients treatment option. 
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Purpose/Objective: To investigate the outcome after PBI 
with 192Ir interstitial HDR brachytherapy in patients with early 
breast cancer. 
Materials and Methods: From August 2003 to May 2014 260 
patients aged 42-85 years (median 67) were enrolled. There 
were 237 infiltrating tumors and 23 DCIS (median tumor size 
9 mm, range 1.25-28) ER and PgR were positive in 236 and 
210 cases respectively. Axillary nodes were negative in 257 
patients; 3 patients had the sentinel positive node, 1 with 
micrometastasis. 29 patients received adjuvant 
chemotherapy, 221 hormonal therapy. Treatment schedule 
was 4 Gy twice a day for 4 days, up to a total dose of 32 Gy 
with an interval between fractions of at least 6 hours. 
Survival was analyzed by Kaplan-Meier estimator. Cosmetic 
results were evaluated, using the Harvard criteria, by 
radiation oncologists and patients, Cohen's k-test of inter-
rater agreement (k-value ranging from 0 to 1) estimated 
concordance between patients and physicians.  
Results: Median follow-up was 74 months (range 2-128). Four 
local relapses (1.5%) were observed 12, 24, 48, 96 months 
after PBI. One regional relapse was observed in the 
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supraclavicular and axillary nodes 7 months after PBI in a 
patient with negative sentinel node. Nine patients developed 
distant metastases, 16 patients a contralateral breast cancer 
and 35 patients a second primary cancer. At the last check-
up 240 patients were alive: 238 with no evidence of cancer, 2 
with metastatic breast cancer. 15 patients died: 4 of 
metastatic breast cancer, 5 of another cancer, 3 of different 
causes. The 5-year probability of breast relapse-free survival, 
nodal relapse-free survival and cause specific-free survival 
were 98.1% (95% CI: 96.3-100 ) 99% (95% CI: 97.7-100 ) and 
99.5%(95% CI: 98.4-100 ) respectively. Acute toxicity occurred 
in 95 patients and late toxicity in 85 patients. From different 
risk factors for toxicity (age, tumor size, hormonal therapy, 
chemotherapy) only tamoxifen, was significant factor for late 
toxicity (p<0.0001). Cosmetic results were excellent/good in 
250 patients, fair in 6, unknown in 4. Overall inter-rater 
agreement by physicians and patients on cosmesis was good 
(K value: 0.67). 
Conclusions: Our data demonstrate that PBI with 192Ir 
interstitial multi-catheter HDR brachytherapy is associated 
with a relapse rate comparable to the best published results 
and low late toxicity.  
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Purpose/Objective: Incidence of breast cancer (BC) is 
increasing in the elderly population because of the increase 
in life expectancy and the diffusion of screening trials. Even 
in patients with BC of excellent prognosis, ipsilateral breast 
tumour recurrence (IBTR) after conservative surgery without 
adjuvant therapy is still very high. IBTR was reduced by 
either radiotherapy (RT) or hormonal therapy but to a greater 
extent by the receipt of both treatments. Whole breast 
irradiation (WBI) remains the standard of care after 
conserving surgery but the management of adjuvant radiation 
therapy in the elderly has become a medical challenge 
because of the poor compliance of patients to conventional 
RT. We analyzed the recurrences rate and the safety profile 
of a subset of patients age 70 years or older of a phase 3 trial 
comparing APBI and WBI. 
Materials and Methods: The trial enrolled 520 women aged 
more than 40 years affected by early BC, with a maximum 
pathological tumour size of 25 mm. Patients were randomly 
assigned in a 1:1 ratio to receive either WBI or APBI using 
IMRT. The APBI arm received a total dose of 30 Gy to the 
tumour bed in 5 daily fractions. The WBI arm received 50 Gy 
in 25 fractions, followed by a boost of 10 Gy in 5 fractions. 
The primary endpoint was occurrence of IBTR; this trial is 
registered with ClinicalTrials.gov, number NCT02104895. 
Results: A total of 114 patients aged more than 70 years 
were analysed (58 in the WBI arm, 56 in the APBI arm). Most 
patients had pathological T1 stage (86%), nuclear grade G1-2 
(73.2%), positive hormonal status (94.7%), negative HER2 
status (83.3%), and luminal-A molecular subtype (74.6%); all 
these features were well balanced between the two arms. 
At a median follow-up of 5.0 years (range 3.4-7.0), the IBTR 
rate was 2% (one case) in the APBI group and 1.9% in the WBI 
group (one case). No significant difference emerged between 
the two groups (log rank test p=0.93). The APBI group 
presented significantly better results considering acute skin 
toxicity (p=0.0001). Major recorded events and safety profile 
of this subgroup of patients were presented in Table 1. 
 
 
Conclusions: Our results confirmed the low rate of IBTR in 
this subgroup of patients, which could benefit in terms of 
quality of life in a reduction of irradiated volume. Omission 
of WBI after conservative surgery in elderly is still 
controversial, according to the indolent behaviour of BC in 
these patients. Further investigations are strongly needed to 
select a subset of tumours of excellent prognosis, such as 
luminal A, to treat with exclusive APBI or hormonal therapy. 
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Purpose/Objective: To report 2-year cosmetic outcome of a 
randomized trial comparing prone and supine whole-breast 
irradiation (WBI) in large breasted patients 
Materials and Methods: Between December 29, 2010, and 
December 12, 2012, 100 patients with at least a (European) 
cup size C presenting for WBI were randomized between 
supine multi-beam and prone tangential field intensity 
modulated radiotherapy. All patients were treated to 40,05 
Gy in 15 fractions, followed by a boost of 10 Gy in 4 fractions 
if indicated. Digital photographs were taken in standard 
conditions before and 2-year after radiotherapy with markers 
on the nipples, the suprasternal notch and the xyphoid. A 
photograph was taken with the arms alongside the body one 
with the arms up. Cosmesis was objectively scored using the 
commercially available BCCT.core software of the INESC 
Porto Breast Research Group (1). A subjective scoring was 
done by 3 observers on a 4-point scale: excellent – good – fair 
– poor. The difference in cosmesis was analyzed with 0 – no 
difference or better cosmesis, 1 – cosmesis one category 
